Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Similares en
SciELO
Compartir
Revista Venezolana de Endocrinología y Metabolismo
versión impresa ISSN 1690-3110
Resumen
ROJANO RADA, Jairo et al. Survival of pancreatic islet β and use of oral hypoglycemic agents: a challenge for the current doctor. Rev. Venez. Endocrinol. Metab. [online]. 2016, vol.14, n.1, pp.5-15. ISSN 1690-3110.
The beta cell is not only able to produce and secrete insulin, but also makes this secretion is at the right time and in the right amount. Postprandial glucose elevations produce an acute secretory response in the beta cell, but in certain diseases such as diabetes mellitus, the scene changes dramatically, resulting in dysfunction, characterized by an altered secretion process and multiple phenotypic changes. In these, nutrients like glucose and fatty acids are chronically elevated, becoming toxic substances that can lead to death of the beta cell itself. Therefore, any therapeutic approach to cure this disease must face the need to replace or avoid this cell decline, it is imperative to mention the role of oral hypoglycemic agents as inhibitors of DPP-4 and analogs of the GLP-1 in protection against failure of the β cell mass.
Palabras clave : Diabetes mellitus; oral hypoglycemic agents; beta pancreatic islets; glucotoxicity.












